Why High-Throughput Labs Lose Sample Traceability at the Bench
Your accessioning is digital, but once samples move into the lab, tracking fragments across paper logs, spreadsheets, and operator memory. Sample status becomes a question only someone physically present can answer, and even then, not reliably.
Why Traceability Gaps Keep Showing Up
Traceability gaps in clinical and genomics labs rarely start as a systems problem. They start as a volume problem. At low throughput, manual tracking works. Operators know which samples are where, reagent lots get recorded at the end of the run, and turnaround time stays within spec because the workflow is small enough to hold in someone's head.
Then volume increases, and each of those manual steps becomes a point where information drops out.
- Sample status tracked on paper or spreadsheets with no real-time visibility into where a sample sits in the workflow
- Reagent usage recorded after the fact, with no validation that the correct lot, concentration, or expiration was used at the point of work
- Operator actions undocumented or inconsistently logged, creating gaps in the audit trail
- Software covers accessioning and reporting. Maybe a LIMS covers major lab steps, but tracing events and metadata across systems is messy.
- Barcode infrastructure available but not integrated into a workflow that enforces its use
- AI or analytics initiatives are stalled because the underlying data isn't structured, consistent, or trustworthy
No single gap causes the breakdown. The breakdown happens because the workflow was designed for documentation, not for control. It asks people to record what happened instead of ensuring the right thing happens at the time of execution.
The Fix: Designing Traceability Into the Workflow
Traceability that holds at scale isn't added as a documentation step. It's designed as a control layer within the workflow itself. The result is a system that captures sample status, enforces valid reagent usage and operator actions at the point of execution, producing audit-ready data as a byproduct of doing the work.
Blanchard Strategic's Approach:
The work starts by mapping where traceability currently breaks down across the sample lifecycle: which steps are tracked digitally, which rely on manual documentation, and which aren't captured at all. That map exposes where the workflow needs system-enforced capture rather than operator-dependent recording.
End-to-end mapping of the sample lifecycle to identify every point where tracking depends on manual action, operator memory, or disconnected systems.
Defining where the workflow needs system-enforced validation: correct reagent, correct sample, correct operator, correct sequence, and error recovery captured at the moment of execution.
Structuring sample, reagent, operator, and instrument data into a unified traceability model that supports real-time visibility, audit readiness, and downstream analytics including AI.
Clarifying what the LIMS should own, what belongs in workflow execution systems, and how data moves between them without gaps or duplication.
Evaluating whether the traceability design holds as volume, operators, sites, and assay complexity increase, before those pressures expose the gaps.
When This Work Is Useful
This engagement fits labs where sample volume has outgrown the tracking systems that were built for an earlier scale.
